The goal of this clinical study is to provide continued access to the study drug(s) to children and adolescents with human immunodeficiency virus type 1 (HIV-1) who completed their participation in an applicable parent study and to monitor for adverse events.
The primary objectives of this study are as follows:
* To provide continued access to the study drug received in the parent protocol or switch to bictegravir/emtricitabine/tenofovir (B/F/TAF) for participants who completed a Gilead parent study evaluating drugs for HIV treatment.
* To evaluate the safety of the study drug(s) in participants with HIV-1.
Protocol Amendment History
12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2024-03-22; most recent amendment 2026-06-09.
Status change: Not Yet Recruiting → Recruiting2024-09-12